Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11131045 | 0.98 | CA2 (0.42) | TDP1CA2CA4FOLH1NAALAD2 | |
| SCHEMBL4519259 | 0.98 | CA2 (0.42) | TDP1CA2CA4FOLH1NAALAD2 | |
| SCHEMBL5489086 | 0.98 | CA2 (0.42) | TDP1CA2CA4FOLH1NAALAD2 | |
| SCHEMBL17616111 | 0.90 | CA2 (0.38) | TDP1CA2CA4FOLH1NAALAD2 | |
| SCHEMBL11302182 | 0.83 | CA2 (0.34) | TDP1CA2CA4FOLH1NAALAD2 | |
| SCHEMBL1688067 | 0.83 | CA2 (0.35) | TDP1CA2CA4FOLH1NAALAD2 | |
| SCHEMBL18127347 | 0.82 | SLC22A6 (0.35) | TDP1CA2CA4SMN1; SMN2GNPAT | |
| SCHEMBL16383645 | 0.82 | SLC22A6 (0.35) | TDP1CA2CA4SMN1; SMN2GNPAT | |
| SCHEMBL14959392 | 0.82 | SLC22A6 (0.35) | TDP1CA2CA4SMN1; SMN2GNPAT | |
| SCHEMBL11298062 | 0.82 | MAPT (0.39) | TDP1FOLH1NAALAD2RIMKLASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | claimed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | claimed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | claimed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| EP-1295891-A4 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE & TECH CORP (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096355-A1 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | RNGTT, RNMT, UPF1 | TDP1 604/4885CA2 3574/4885CA4 4062/4885 |
| US-20030208050-A1 | Nucleoside derivatives | RIMKLA, MTHFD1, AADAT | TDP1 99/4885CA2 3081/4885CA4 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.